InflaRx (IFRX) Common Equity (2016 - 2026)
InflaRx (IFRX) posted Common Equity of $43.2 million for Q1 2026, down 10.72% sequentially from $48.4 million in Q4 2025, and down 41.73% YoY from $74.1 million in Q1 2025.
InflaRx (IFRX) Common Equity (2016 - 2026) Analysis & Trends
InflaRx has reported Common Equity for 11 years, with the latest figure at $43.2 million in Q1 2026.
- Quarterly Common Equity fell 41.73% year-over-year to $43.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.2 million (down 41.73% YoY) and the FY2025 annual result came in at $47.0 million, down 29.37% from the prior year.
- Common Equity fell to $43.2 million in Q1 2026 per IFRX's latest filing, from $48.4 million in the prior quarter.
- Over five years, Common Equity peaked at $135.7 million in Q2 2023 and troughed at $43.2 million in Q1 2026.
- A 5-year average of $86.9 million and a median of $88.5 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity gained 28.11% in 2023, then sank 44.18% in 2024.
- Over 5 years, Common Equity stood at $90.1 million in 2022, then gained by 22.45% to $110.4 million in 2023, then sank by 40.54% to $65.6 million in 2024, then fell by 26.29% to $48.4 million in 2025, then retreated by 10.72% to $43.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $43.2 million, $48.4 million, and $53.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 169.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.19 Mn |
| Dec 31, 2025 | 48.37 Mn |
| Sep 30, 2025 | 53.04 Mn |
| Jun 30, 2025 | 64.57 Mn |
| Mar 31, 2025 | 74.12 Mn |
| Dec 31, 2024 | 65.63 Mn |
| Sep 30, 2024 | 71.69 Mn |
| Jun 30, 2024 | 88.47 Mn |
| Mar 31, 2024 | 102.94 Mn |
| Dec 31, 2023 | 110.37 Mn |
| Sep 30, 2023 | 128.44 Mn |
| Jun 30, 2023 | 135.73 Mn |
| Mar 31, 2023 | 84.34 Mn |
| Dec 31, 2022 | 90.14 Mn |
| Sep 30, 2022 | 100.26 Mn |
| Jun 30, 2022 | 108.98 Mn |
| Mar 31, 2022 | 106.76 Mn |
| Dec 31, 2021 | 120.44 Mn |
| Sep 30, 2021 | 135.89 Mn |
| Jun 30, 2021 | 148.86 Mn |